date,title,source
Oct-22-18,"Investor Expectations to Drive Momentum within ChannelAdvisor, WideOpenWest, Arcos Dorados, Mesoblast, Ferrari N.V, and Weatherford International  Discovering Underlying Factors of Influence",GlobeNewswire
Oct-24-18,Mesoblast Expands Partnership With JCR Pharmaceuticals for Treatment of Wound Healing in Epidermolysis Bullosa,GlobeNewswire
Nov-09-18,Mesoblast to Host Analyst Call on Results of End-Stage Heart Failure Trial Being Presented at 2018 American Heart Association Scientific Sessions,GlobeNewswire
Nov-15-18,"Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights",GlobeNewswire
Nov-15-18,"Mesoblast Financial Results Webcast for Quarter Ended September 30, 2018",GlobeNewswire
Nov-26-18,Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China,GlobeNewswire
Nov-29-18,"Recent Analysis Shows HudBay Minerals, Meridian Bioscience, ArQule, Mesoblast, Concho Resources, and Liberty Global Market Influences  Renewed Outlook, Key Drivers of Growth",GlobeNewswire
Dec-13-18,Meetings Held With FDA Support Mesoblasts Planned Regulatory Filing for Commercialization of Remestemcel-L in Acute GVHD,GlobeNewswire
Dec-19-18,Mesoblast Makes Executive Appointment to Drive Product Commercialization,GlobeNewswire
Dec-24-18,Mesoblast to Present at 2019 Biotech Showcase in San Francisco,GlobeNewswire
Dec-28-18,Mesoblast Corporate Review,GlobeNewswire
Jan-07-19,Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco,GlobeNewswire
Jan-07-19,Phase 3 Trial of Mesoblasts Cell Therapy in Chronic Heart Failure Completes Recruitment,GlobeNewswire
Jan-14-19,Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs,GlobeNewswire
Feb-04-19,"New Research Coverage Highlights Symantec, YY, Workiva, Exponent, Ferroglobe, and Mesoblast  Consolidated Revenues, Company Growth, and Expectations for 2019",GlobeNewswire
Feb-13-19,"Mesoblast Financial Results Webcast for Half Year, Q2 Ended December 31, 2018",GlobeNewswire
Feb-19-19,Final Patient Dosed in Mesoblast Phase 3 Trial of Revascor Cell Therapy for Advanced Heart Failure,GlobeNewswire
Feb-20-19,"Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018",GlobeNewswire
Mar-13-19,Mesoblast Features at Upcoming U.S. Investor Conferences,GlobeNewswire
Mar-22-19,U.S. Healthcare Leader Joseph R. Swedish Appointed Mesoblast Chairman,GlobeNewswire
Mar-25-19,Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa,GlobeNewswire
Mar-26-19,Memorandum of Understanding for Confirmatory Trial to Support Marketing Approval of Revascor for Reduction of Gastrointestinal Bleeding in LVAD Patients,GlobeNewswire
Apr-05-19,Mesoblast to Present at Upcoming Global Life Sciences Conference in London,GlobeNewswire
Apr-09-19,Should You Be Pleased About The CEO Pay At Mesoblast Limited's (ASX:MSB),Simply Wall St.
Apr-16-19,FDA Agrees to Rolling Review of Mesoblasts Biologics License Application for Its Cell Therapy in Children With Steroid-Refractory Acute Graft Versus Host Disease,GlobeNewswire
May-15-19,What Kind Of Shareholders Own Mesoblast Limited (ASX:MSB)?,Simply Wall St.
May-17-19,Mesoblast to Present at 2019 RBC Capital Markets Global Healthcare Conference,GlobeNewswire
May-23-19,Mesoblast Keynote Presentations to Feature at 2019 Annual Meeting of the International Society for Cell and Gene Therapy,GlobeNewswire
May-29-19,Mesoblast Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for remestemcel-L in the Treatment of Acute Graft Versus Host Disease,GlobeNewswire
May-30-19,"Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019",GlobeNewswire
May-30-19,Mesoblast Starts Rolling BLA Submission for Remestemcel-L,Zacks
May-30-19,"Mesoblast Financial Results Webcast for Period Ended March 31, 2019",GlobeNewswire
Jun-11-19,Mesoblast and JCR Pharmaceuticals Expand Japan License Agreement to Use of Mesenchymal Stem Cells in Newborns With Insufficient Blood Flow to the Brain,GlobeNewswire
Jun-14-19,Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease,GlobeNewswire
